EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates

Serge Ferrari, Magaly Hars, Emmanuel Biver, Brigitte Uebelhart, Anne-Catherine Joly, François Herrmann, Christian Meier, Kurt Lippuner

Osteoporosis International · 2026

DOI: 10.1007/s00198-026-08115-1 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Osteoporosis International, 2026. Verfasst von Serge Ferrari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Bone Diseases, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Rue Gabrielle-Perret-Ge…. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporosis, Postmenopausal, Diphosphonates, Denosumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amgen Switzerland AG, University of Geneva.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigated the timing and effects of zoledronate infusions in long-term denosumab users having reached T-score targets (BMD > -2.0 T-score). Findings support that early and multiple zoledronate injections are needed to preserve as much BMD as possible after stopping denosumab. PURPOSE: This study evaluated the effects of zoledronate (Zol) administration and the need for multiple infusions to prevent bone loss after stopping denosumab (Dmab) in long-term users, and the influence of previous bisphosphonates (BPs) exposure. METHODS: This was a multicentric, randomized, open-label study, including 44 post-menopausal women treated with Dmab > 2 years and reaching BMD T-scores > -2.0. Patients without pre-Dmab BPs were randomized into 3 groups receiving Zol at 6 months (6 M, n = 12) or 9 months (9 M, n = 11) after the last Dmab, or to a group receiving Zol if CTX > 644 ng/l or BMD decreased ≥ 5% (OBS, n = 11). A parallel observational group exposed to pre-Dmab BPs (OBS-BPs, n = 10) received Zol under the same criteria as the OBS group. Zol was re-administered during the 2‑year follow‑up according to CTX threshold or BMD loss criteria. Co-primary outcomes were lumbar spine BMD changes 1-year post-Zol and frequency of Zol treatments required. RESULTS: A majority of post-Dmab patients without previous BPs required multiple Zol infusions (median 2, range 1-5), while most patients in OBS group with previous BPs needed only one Zol. Median LS BMD changes 12 and 24 months post-Zol were similar between groups. However, LS BMD changes at 12 months after the end of the last Dmab dose effect were numerically larger in 9 M group (-8.25%) and OBS group (-8.13%) than in 6 M (-4.71%) and OBS-BPs (-4.62%) groups. CONCLUSION: Findings support that early and multiple Zol injections are needed better to preserve BMD after stopping Dmab in long-term users.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsOsteoporosis, PostmenopausalDiphosphonatesDenosumabImidazolesHumansFemaleZoledronic AcidBone DensityAgedDrug Administration ScheduleMiddle AgedLumbar VertebraeTreatment InterruptionInfusions, Intravenous

Stichwörter der Autor:innen

antiresorbersbone turnover biochemical markersosteoporosispost-menopausal womensubsequent treatment

Substanzen

Zoledronic AcidBone Density Conservation AgentsDiphosphonatesDenosumabImidazoles

Autor:innen und Institutionen

  • Division of Bone Diseases, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Rue Gabrielle-Perret-Gentil 4, CH-1205, Geneva, Switzerland. Serge.Ferrari@unige.ch.
  • Division of Bone Diseases, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Rue Gabrielle-Perret-Gentil 4, CH-1205, Geneva, Switzerland.
  • Division of Geriatrics, Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Division of Endocrinology, Diabetology & Metabolism, University Hospital and University of Basel, Basel, Switzerland.
  • Department of Osteoporosis, Bern University Hospital, University of Bern, Bern, Switzerland.

Förderung

  • Amgen Switzerland AG
  • University of Geneva

Zitieren

APA

Ferrari, S., Hars, M., Biver, E., Uebelhart, B., Joly, A. C., Herrmann, F., Meier, C., & Lippuner, K. (2026). Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates. Osteoporosis International. https://doi.org/10.1007/s00198-026-08115-1

Vancouver

Ferrari S, Hars M, Biver E, Uebelhart B, Joly AC, Herrmann F, et al. Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates. Osteoporosis International. 2026. doi:10.1007/s00198-026-08115-1

BibTeX
@article{Ferrari2026,
  author = {Ferrari, Serge and Hars, Magaly and Biver, Emmanuel and Uebelhart, Brigitte and Joly, Anne-Catherine and Herrmann, François and Meier, Christian and Lippuner, Kurt},
  title = {Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates},
  journal = {Osteoporosis International},
  year = {2026},
  doi = {10.1007/s00198-026-08115-1}
}
Kostenlos starten →